The point-of-care test is designed for the qualitative presumptive detection of specific IgM and IgG antibodies to SARS-CoV-2 in a fingerstick blood sample.
The testing products, developed by China-based 3D Medicines, have received CE marking and approval from the Chinese National Medical Products Administration, Todos said.
PreCheck Health has an initial order of 30,000 tests and will register the product in Ecuador. The two firms have a similar distribution agreement covering Russia.
The Shenzhen Mammoth Public Welfare Foundation, which BGI sponsors, has also raised funding to purchase PCR and automate sample preparation instruments.